DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Healthcare
Author Program NEWCreate Narrative
SN. logo

Smith & Nephew plc Stock Price

LSE:SN. Community·UK£8.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 88 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SN. Share Price Performance

UK£10.09
-3.96 (-28.22%)
​
UK£12.57
Fair Value
UK£10.09
-3.96 (-28.22%)
19.8% undervalued intrinsic discount
UK£12.57
Fair Value
Price UK£10.09
AnalystConsensusTarget UK£12.57
Mon, 7 Sep 26
Fair ValueUK£12.57
Share Pricen/a

SN. Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value UK£12.57 19.8% undervalued intrinsic discount

Orthopaedic And Wound Care Advances Will Drive Global Reach And Clinical Outcomes

0users have liked this narrative
0users have commented on this narrative
47users have followed this narrative
SN. logo
Smith & Nephew
19.8% undervalued intrinsic discount
Updated

Orthopaedic And Wound Care Advances Will Drive Global Reach And Clinical Outcomes

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 7 Sep
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
SN. logo

SN.: Robotic Surgery Advances And AI Guidance Will Drive Future Upside

Fair Value: UK£12.57 19.8% undervalued intrinsic discount
47 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with solid track record and pays a dividend.

1 Risk
6 Rewards
View Full Analysis

Smith & Nephew plc Key Details

US$6.3b

Revenue

US$2.0b

Cost of Revenue

US$4.3b

Gross Profit

US$3.7b

Other Expenses

US$635.0m

Earnings

Last Reported Earnings
Jun 27, 2026
Next Reporting Earnings
n/a
0.75
68.44%
10.08%
69.3%
View Full Analysis

About SN.

Founded
1856
Employees
17000
CEO
Deepak Nath
WebsiteView website
www.smith-nephew.com

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Recent SN. News & Updates

User avatar
Narrative Update • Sep 07

SN.: Robotic Surgery Advances And AI Guidance Will Drive Future Upside

Analysts have modestly adjusted their price target for Smith & Nephew to £12.57 from £12.91, reflecting slightly updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News for Smith & Nephew Smith & Nephew plans a Chief Financial Officer transition, with John Rogers intending to leave the role on 30 September 2026 and Senior Vice President Finance and Group Controller Pierre Palassian set to act as interim CFO.
User avatar
Narrative Update • Aug 19

SN.: Robotic Surgery Partnership Will Drive Future Upside

Analysts have modestly reduced their price target on Smith & Nephew to £12.91 from £13.26, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What’s in the News for Smith & Nephew Chief Financial Officer John Rogers plans to leave Smith & Nephew on 30 September 2026 to take an external role in the US.

Recent updates

No updates

Smith & Nephew plc Competitors

CTEC logo

Convatec Group

Symbol: LSE:CTEC
Market cap: UK£4.2b
SPI logo

Spire Healthcare Group

Symbol: LSE:SPI
Market cap: UK£985.5m
CVSG logo

CVS Group

Symbol: LSE:CVSG
Market cap: UK£886.3m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide